Race Oncology has announced it has executed a global distribution agreement with UK-based, Durbin PLC.
Durbin distributes pharmaceutical and healthcare products to 180 countries worldwide.
They have global expertise in managed access programs, such as named patient programs (NPP).
Under the agreement, Durbin will handle all the warehousing, invoicing, customer service and distribution of Bisantrene for a number of countries around the world (see ‘Detailed Agreement Terms’ below).
“This is more than a global logistics agreement,” said Race CEO, Peter Molloy. “Durbin’s expertise in managed access and named patient programs makes them an important strategic partner for Race.”
Race previously advised that it was seeking to establish NPP sales in four countries initially: France, Italy, Turkey and Korea.
“With Durbin’s help, we can now pursue named patient sales in many other countries in parallel. The Durbin agreement significantly expands our NPP opportunity for Bisantrene.”
Detailed Agreement Terms
The agreement covers the UK, Ireland, Benelux, Nordics, Central & Eastern Europe, Australia, New Zealand, Israel, Middle East, South Africa and other countries as agreed between the parties from time to time.
The agreement has an initial term of three years, during which time it can be terminated by either party on six months’ notice.
Following this initial period, the agreement will continue in force but can be terminated by either party on three months’ notice.
Durbin will take Bisantrene shipments on consignment and there are no minimum purchase orders under the agreement.